Glycosuria News and Research

RSS

SARS-CoV-2 infection causes specific kidney proximal tubular injury

SARS-CoV-2-associated acute kidney injury (AKI) is one of the more frequently encountered organ involvements in COVID-19 - in as many as 80% of critically ill patients, according to a recent study.

8 Jun 2020

Acute kidney injury in intensive-care COVID-19 patients

71 patients with severe lung injury were admitted to four intensive care units at Bordeaux University Hospital and their data were collected and evaluated over a period of six weeks (March/April 2020). AKI was defined using KDIGO criteria and ADQI according to the Acute Disease Quality Initiative (ADQI) 16 workgroup.

8 Jun 2020

Gestational diabetes mellitus screening provides more health benefits to pregnant women

A local research study conducted by KK Women's and Children's Hospital and Duke-NUS Graduate Medical School has found that pregnant patients benefit most from gestational diabetes mellitus (GDM) screening as it allows for timely interventions and brings about health benefits that far outweigh the cost.

18 Nov 2015

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Intarcia Therapeutics, Inc. today announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of its late-stage investigational candidate ITCA 650 (exenatide delivered continuously via a small matchstick-size subcutaneous osmotic mini-pump just once or twice yearly) at the 75th Scientific Sessions of the American Diabetes Association.

8 Jun 2015

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Fera Pharmaceuticals is pleased to announce the launch of Neptazane (Methazolamide) 25 mg and 50 mg tablets. Both strengths are available in 90 count bottles.

3 Jul 2010

Advances in the management of diabetes mellitus

The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.

1 Sep 2008